NeoGenomics, Inc. (NEO) Touches $11.55 High on May, 23; Youngevity International (YGYI) Shorts Decreased By 72%

May 23, 2018 - By David Stenberg

Youngevity International, Inc. (NASDAQ:YGYI) Logo

Youngevity International Inc (NASDAQ:YGYI) had a decrease of 72% in short interest. YGYI’s SI was 1,400 shares in May as released by FINRA. Its down 72% from 5,000 shares previously. With 20,900 avg volume, 0 days are for Youngevity International Inc (NASDAQ:YGYI)’s short sellers to cover YGYI’s short positions. The SI to Youngevity International Inc’s float is 0.03%. The stock decreased 2.64% or $0.1004 during the last trading session, reaching $3.6996. About 1,052 shares traded. Youngevity International, Inc. (NASDAQ:YGYI) has declined 22.47% since May 23, 2017 and is downtrending. It has underperformed by 34.02% the S&P500.

The stock of NeoGenomics, Inc. (NASDAQ:NEO) reached all time high today, May, 23 and still has $12.13 target or 5.00% above today’s $11.55 share price. This indicates more upside for the $931.13 million company. This technical setup was reported by Barchart.com. If the $12.13 PT is reached, the company will be worth $46.56M more. The stock increased 0.79% or $0.09 during the last trading session, reaching $11.55. About 85,458 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has risen 7.47% since May 23, 2017 and is uptrending. It has underperformed by 4.08% the S&P500.

Since May 10, 2018, it had 0 insider purchases, and 2 insider sales for $1.03 million activity. BALLIET JENNIFER sold $146,055 worth of stock. ROSS STEVEN A had sold 81,999 shares worth $883,949 on Thursday, May 10.

Among 11 analysts covering NeoGenomics (NASDAQ:NEO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. NeoGenomics had 19 analyst reports since September 3, 2015 according to SRatingsIntel. On Friday, March 11 the stock rating was initiated by Benchmark with “Buy”. Roth Capital reinitiated the stock with “Buy” rating in Wednesday, May 11 report. The firm has “Equal-Weight” rating by First Analysis given on Wednesday, May 2. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Friday, May 26 by Roth Capital. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Overweight” rating by First Analysis on Tuesday, October 4. The firm has “Overweight” rating by Cantor Fitzgerald given on Thursday, December 15. The company was downgraded on Monday, September 11 by BTIG Research. BTIG Research maintained NeoGenomics, Inc. (NASDAQ:NEO) on Friday, May 26 with “Buy” rating. The firm earned “Buy” rating on Thursday, September 3 by Roth Capital. TH Capital reinitiated NeoGenomics, Inc. (NASDAQ:NEO) on Monday, October 26 with “Buy” rating.

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.45, from 1.28 in 2017Q3. It is negative, as 15 investors sold NeoGenomics, Inc. shares while 45 reduced holdings. 15 funds opened positions while 35 raised stakes. 63.75 million shares or 2.01% more from 62.50 million shares in 2017Q3 were reported. Falcon Point Ltd Liability Co has 2.39% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 1.60 million shares. Citigroup Inc holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 11,624 shares. Suntrust Banks invested 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Gabelli Funds Llc accumulated 476,400 shares. Gp invested in 38,142 shares. Alliancebernstein Ltd Partnership holds 0% in NeoGenomics, Inc. (NASDAQ:NEO) or 62,700 shares. 1.10 million are held by Granahan Invest Mgmt Ma. Rhumbline Advisers reported 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Fulton National Bank Na has 0.04% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 70,042 shares. Gamco Invsts Et Al holds 108,900 shares or 0.01% of its portfolio. Cortina Asset Mgmt Ltd Liability invested 0.27% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Meristem Llp stated it has 14,476 shares or 0.05% of all its holdings. New York-based Stone Ridge Asset Mngmt Limited Liability has invested 0.02% in NeoGenomics, Inc. (NASDAQ:NEO). State Board Of Administration Of Florida Retirement Systems owns 17,810 shares. Guggenheim Cap Ltd Company invested 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO).

Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on July, 24. They expect $0.03 EPS, up 50.00% or $0.01 from last year’s $0.02 per share. NEO’s profit will be $2.42 million for 96.25 P/E if the $0.03 EPS becomes a reality. After $0.02 actual EPS reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts 50.00% EPS growth.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $931.13 million. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It currently has negative earnings. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

Another recent and important NeoGenomics, Inc. (NASDAQ:NEO) news was published by Seekingalpha.com which published an article titled: “NeoGenomics’ (NEO) CEO Doug VanOort on Q1 2018 Results – Earnings Call Transcript” on May 01, 2018.

Youngevity International, Inc. develops and distributes health and nutrition related services and products through independent direct selling network in the United States and internationally. The company has market cap of $79.68 million. It operates through two divisions, Direct Selling and Commercial Coffee. It currently has negative earnings. The firm offers approximately 5,000 products, including nutritional supplements; sports and energy drinks; health and wellness products; weight loss products; lifestyle products, such as spa, bath, home, and garden products; gourmet coffee; apparel and fashion accessories; skincare and cosmetics; lifestyle services; digital products comprising scrap books and memory books, packaged foods, pharmacy discount cards, and clothing and jewelry lines; pet care products; telecare health services; and business lending services.

More important recent Youngevity International, Inc. (NASDAQ:YGYI) news were published by: Nasdaq.com which released: “Youngevity International, Inc. (YGYI) to Host First Quarter 2018 Earnings Conference Call to Review Financial Results …” on May 08, 2018, also Globenewswire.com published article titled: “Youngevity International, Inc. Announces First Quarter Results”, Seekingalpha.com published: “Youngevity International’s (YGYI) CEO Steve Wallach on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. More interesting news about Youngevity International, Inc. (NASDAQ:YGYI) was released by: Globenewswire.com and their article: “Youngevity Announces Asia Convention Event Is Being Held Next Month in Malaysia” with publication date: April 25, 2018.

NeoGenomics, Inc. (NASDAQ:NEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: